FDA approves Basilea Pharmaceutica's antibiotic, Zevtera, to treat antibiotic-resistant infections.
The FDA has approved Basilea Pharmaceutica's antibiotic, Zevtera, to treat three types of bacterial infections: Staphylococcus aureus bloodstream infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia. Zevtera, an advanced-generation cephalosporin antibiotic, expands treatment options for patients with antibiotic-resistant infections. The Centers for Disease Control and Prevention (CDC) reports that over 2.8 million antimicrobial-resistant infections occur annually in the US.
April 03, 2024
12 Articles